Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both Betasalic ointment and 5% minoxidil resulted in acceptable hair regrowth for patients with alopecia areata over a three-month period, with any adverse effects being transient.

This article reviews the treatment options for tinea capitis, suggesting that itraconazole, terbinafine, and fluconazole are effective and safe alternatives to griseofulvin but reports no new clinical results.

This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.

In this study, polymeric micelles containing retinoic acid were found to improve targeted delivery to hair follicle structures in human skin more efficiently than a marketed retinoic acid gel, suggesting potentially safer and more effective acne treatment.

This narrative review discusses the use of cyclosporin for various skin diseases in small animals and notes minimal side effects at therapeutic doses, but reports no original clinical findings.

This review examines the main absorption sites and influencing factors for orally administered drugs, highlighting variables such as solubility and gastrointestinal conditions that affect drug absorption in the small intestine and the development of effective drug delivery systems.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

This review discusses evidence-based treatments for common hair loss forms, noting robust support for androgenetic alopecia therapies but limited long-term data and fewer high-quality studies for alopecia areata and cicatricial alopecias.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

This review outlines the mechanisms, clinical features, and management strategies for alopecia areata and presents no new experimental findings.

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

This letter details a case report on platelet-rich plasma treatment for a patient with treatment-resistant frontal fibrosing alopecia, but it does not provide new clinical results.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

This study found that a new hydrogel formulation of basic fibroblast growth factor showed promise in promoting hair regrowth and reducing inflammation in testosterone-treated mice.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

In this study, RT1640 was found to promote hair pigment system regeneration and expand melanocyte stem cell pools in a mouse model, suggesting potential applications for aging-related hair disorders.

This article discusses the features and increasing prevalence of frontal fibrosing alopecia, a type of scarring hair loss, and reports no new clinical results.

Hair transplantation can successfully treat stubborn alopecia areata.

This review discusses lipid-polymer hybrid nanoparticles for dermatological applications, outlining their structural and formulation advancements, but reports no new clinical results and calls for further research on their therapeutic potential.

This study found that two sessions of platelet-rich plasma mesotherapy significantly improved symptoms in patients with corticosteroid-induced rosacea-like dermatitis without further treatment.

This review explores the potential role of caveolin-1 in cicatricial alopecia, particularly frontal fibrosing alopecia, and discusses possibilities for targeted therapies without providing new research results.

This source underscores the need for a multidisciplinary effort to raise awareness of Demodex and demodicosis, suggesting that prioritizing research, diagnostics, and treatment development could enhance global health outcomes and improve quality of life for affected individuals.

This review study found that vesicular carriers like liposomes, niosomes, invasomes, and transferosomes can enhance drug penetration through follicles, benefiting treatments for alopecia, acne, and infections, as well as potentially facilitating systemic delivery of antihypertensive drugs and insulin.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This review discusses various treatments for noncicatricial alopecias, such as androgenetic alopecia and alopecia areata, including mesotherapy, microneedling, and platelet-rich plasma therapy, noting that outcomes vary across these procedures.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

This case report documented a 20-year-old male with alopecia areata who experienced slight hair regrowth following treatment with cyclosporine and methylprednisolone, highlighting the importance of individualized treatment plans and consideration of medication side effects.